Published in Curr Opin Immunol on October 01, 1998
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med (1999) 1.88
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood (2005) 1.42
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med (2005) 1.37
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol (2000) 1.35
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci U S A (2000) 1.31
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr (2007) 1.25
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol (2001) 1.24
Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism. J Immunol (2010) 1.13
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer (2005) 1.10
Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol (2003) 1.05
The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL. J Immunol (2011) 0.97
Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis (1999) 0.96
Immediate early gene X-1 interacts with proteins that modulate apoptosis. Biochem Biophys Res Commun (2004) 0.96
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer (2007) 0.94
Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells. Evid Based Complement Alternat Med (2013) 0.93
Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87. World J Gastroenterol (2001) 0.92
Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol (2005) 0.92
Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One (2014) 0.91
Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol (2002) 0.91
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther (2010) 0.90
TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer (2003) 0.90
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology (2004) 0.90
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord (2010) 0.88
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells. J Immunol (2010) 0.87
Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Hum Immunol (2008) 0.87
Interplay between Helicobacter pylori and immune cells in immune pathogenesis of gastric inflammation and mucosal pathology. Cell Mol Immunol (2010) 0.87
Retracted Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol (2005) 0.86
Staphylococcus aureus and Salmonella enterica serovar Dublin induce tumor necrosis factor-related apoptosis-inducing ligand expression by normal mouse and human osteoblasts. Infect Immun (2001) 0.86
Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis. PLoS One (2012) 0.86
Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. World J Gastroenterol (2003) 0.83
Helicobacter pylori enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in human gastric epithelial cells. World J Gastroenterol (2004) 0.83
Protein kinase Cδ and caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. J Cell Biochem (2010) 0.81
TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. J Leukoc Biol (2010) 0.81
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects. World J Gastroenterol (2004) 0.80
Gene expression profiling associated with angiotensin II type 2 receptor-induced apoptosis in human prostate cancer cells. PLoS One (2014) 0.80
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther (2007) 0.80
Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29. World J Gastroenterol (2003) 0.79
Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal (2011) 0.79
Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. PLoS One (2014) 0.78
Dexamethasone inhibits TRAIL- and anti-cancer drugs-induced cell death in A549 cells through inducing NF-kappaB-independent cIAP2 expression. Cancer Res Treat (2004) 0.78
Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells. Apoptosis (2014) 0.77
PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy. Int J Nanomedicine (2015) 0.76
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells. Ann Surg Innov Res (2009) 0.76
Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation. BMC Immunol (2012) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol (2011) 0.75
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L. Int J Mol Sci (2016) 0.75
Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity. Cell Death Dis (2016) 0.75
[Not Available]. J Oncol (2009) 0.75
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 6.85
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34
Fas transduces activation signals in normal human T lymphocytes. J Exp Med (1993) 3.04
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol (1998) 2.49
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol (1994) 2.10
Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol (1996) 2.07
Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells. J Immunol (1996) 1.76
Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75
Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol (1995) 1.70
Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med (1997) 1.63
Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol (2000) 1.58
Relationship between epidermal Langerhans cell density ATPase activity and the induction of contact hypersensitivity. J Immunol (1981) 1.57
HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ (2002) 1.54
gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol (1994) 1.50
In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest (1998) 1.36
Immune-mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage apoptosis. J Infect Dis (2001) 1.35
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
Fas-mediated cytotoxicity by intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice. Gastroenterology (1997) 1.33
Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol (1999) 1.30
An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol (1996) 1.27
JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Eur J Immunol (1996) 1.27
Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. J Clin Invest (1996) 1.25
Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol (1994) 1.22
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum (1995) 1.20
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ (1999) 1.19
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol (1997) 1.16
T cell responses to Mls determinants are restricted by cross-reactive MHC determinants. J Immunol (1985) 1.16
Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol (1996) 1.14
Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J Immunol (1999) 1.14
Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol (1995) 1.12
The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest (1998) 1.09
Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells. J Immunol (1996) 1.07
CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur J Immunol (1997) 1.05
Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses (1999) 1.04
HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology (1996) 1.01
Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Photochem Photobiol (1989) 1.00
Cross-reactive recognition by antigen-specific, major histocompatibility complex-restricted T cells of a mitogen derived from Mycoplasma arthritidis is clonally expressed and I-E restricted. Eur J Immunol (1986) 0.99
CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis. J Exp Med (1998) 0.99
The use of transfected fibroblasts and transgenic mice establishes that stimulation of T cells by the Mycoplasma arthritidis mitogen is mediated by E alpha. J Immunol (1990) 0.96
Changes in antigen-presenting cell function in the spleen and lymph nodes of ultraviolet-irradiated mice. Transplantation (1982) 0.95
Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin. Arthritis Rheum (1997) 0.94
Regulation of the Fas lytic pathway in cloned CTL. J Immunol (1996) 0.90
Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine (1997) 0.90
Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem Biophys Res Commun (1996) 0.90
Potential for involvement of Fas antigen/Fas ligand interaction in apoptosis of epithelial cells by intraepithelial lymphocytes in murine small intestine. Lab Invest (1997) 0.90
Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol (1999) 0.89
ZAP-70 tyrosine kinase is required for the up-regulation of Fas ligand in activation-induced T cell apoptosis. J Immunol (1997) 0.87
Experimental photoimmunology: immunologic ramifications of UV-induced carcinogenesis. J Invest Dermatol (1981) 0.86
The effects of ultraviolet irradiation on the generation of anti-tumor cytotoxic effector cell responses in vitro. J Immunol (1981) 0.85
Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm Res (1997) 0.85
Receptors and ligands that mediate activation-induced death of T cells. Springer Semin Immunopathol (1998) 0.83
Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation (1991) 0.83
Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood (1991) 0.83
The effects of high-dose UV exposure on murine Langerhans cell function at exposed and unexposed sites as assessed using in vivo and in vitro assays. J Invest Dermatol (1983) 0.83
CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. J Immunol (1996) 0.82
Extensive apoptosis of lung T-lymphocytes maintained in vitro. Am J Respir Cell Mol Biol (1996) 0.81
CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses. J Immunol (1998) 0.80
Emergence of blueberry maggot flies (Diptera: tephritidae) from mulches and soil at various depths. Environ Entomol (2012) 0.80
Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells. J Immunol (1998) 0.79
Genetic identification of a locus linked to the rat MHC that codes for a membrane antigen detectable with cytotoxic lymphocytes. J Immunol (1978) 0.79
Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype. J Immunol (1986) 0.79
Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol (1993) 0.78
Evidence for two functionally distinct cross-reactive tumor antigens associated with ultraviolet light and chemically induced tumors. Transplantation (1982) 0.78
Abrogation of epidermal antigen-presenting cell function by ultraviolet radiation administered in vivo. Transplantation (1983) 0.78
T cell proliferative responses to a mitogen derived from Mycoplasma arthritidis are controlled by the accessory cell. J Immunol (1983) 0.78
Blocking of the B7-CD28 pathway increases the capacity of FasL+ (CD95L+) dendritic cells to kill alloactivated T cells. Adv Exp Med Biol (1997) 0.78
Ultraviolet radiation and modulation. Immunol Ser (1989) 0.77
Inducible resistance to Fas-mediated apoptosis in primary B lymphocytes. Adv Exp Med Biol (1996) 0.77
Avoidance tests with Folsomia candida for the assessment of copper contamination in agricultural soils. Environ Pollut (2011) 0.76
Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol (1999) 0.75
Blocking of the B7-CD28 pathway increases apoptosis induced in activated T cells by in vitro-generated CD95L (FasL) positive dendritic cells. Transplant Proc (1997) 0.75
Different specificities of cloned T cells assessed by in vitro proliferation assays and by the ability to mediate skin graft rejection in vivo. Transplantation (1987) 0.75
Evaluation of naturally occurring cell-mediated cytotoxic activity in normal and UV-irradiated mice. Transplantation (1983) 0.75
The I-J dilemma: new developments. Immunol Today (1984) 0.75
The LEW.BN(2R) strain: a recombinant in the rat MHC. J Immunol (1980) 0.75
Systemic immunosuppression induced by peritoneal photodynamic therapy. Am J Obstet Gynecol (1988) 0.75
Influence of fertilization on the Colorado potato beetle, Leptinotarsa decemlineata, in organic potato production. Environ Entomol (2008) 0.75
Ground and rove beetles (Coleoptera: Carabidae and Staphylinidae) are affected by mulches and weeds in highbush blueberries. Environ Entomol (2012) 0.75
Analysis of cytotoxic effector cell populations by kinetic and monolayer adsorption techniques. J Immunol (1980) 0.75
Effect of Mlsa on antigen presentation to class II-restricted T cells. J Immunol (1988) 0.75